Wolfe Eye Clinic

Summary

Wolfe Eye Clinic is a medical facility located in West Des Moines, Iowa. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Retinal Disease, Diabetic Macular Edema, Retinal Degeneration and other specialties. Wolfe Eye Clinic is involved with conducting 50 clinical trials across 43 conditions. There are 1 research doctors associated with this hospital, such as Derek Bitner, MD.

Top PIs

Clinical Trials running at Wolfe Eye Clinic

Age-Related Macular Degeneration

Macular Degeneration

Lazy Eye

Choroidal Neovascularization

Retinal Degeneration

Retinal Disease

None

Choroidal neovascularization

Wet AMD

Diabetic Macular Edema

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.

Recruiting

2 awards

Phase 3

2 criteria

PDS Implant with Ranibizumab

for Age-Related Macular Degeneration

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Recruiting

2 awards

Phase 3

3 criteria

Avacincaptad Pegol

for Macular Degeneration

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.

Recruiting

1 award

N/A

3 criteria